12.89
price up icon3.87%   0.48
after-market Handel nachbörslich: 12.89
loading
Schlusskurs vom Vortag:
$12.41
Offen:
$12.42
24-Stunden-Volumen:
288.51K
Relative Volume:
0.51
Marktkapitalisierung:
$910.76M
Einnahmen:
$62.71M
Nettoeinkommen (Verlust:
$-112.51M
KGV:
-8.5364
EPS:
-1.51
Netto-Cashflow:
$-96.01M
1W Leistung:
+1.42%
1M Leistung:
+10.74%
6M Leistung:
-12.79%
1J Leistung:
+53.45%
1-Tages-Spanne:
Value
$12.34
$12.95
1-Wochen-Bereich:
Value
$12.16
$12.95
52-Wochen-Spanne:
Value
$8.32
$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name
Firmenname
Zymeworks Inc.
Name
Telefon
604-678-1388
Name
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
Mitarbeiter
170
Name
Twitter
@ZymeworksInc
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ZYME's Discussions on Twitter

Vergleichen Sie ZYME mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ZYME
Zymeworks Inc.
12.89 910.76M 62.71M -112.51M -96.01M -1.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-20 Eingeleitet TD Cowen Buy
2024-12-16 Hochstufung JP Morgan Neutral → Overweight
2024-11-07 Hochstufung Leerink Partners Market Perform → Outperform
2024-11-01 Herabstufung Wells Fargo Overweight → Equal Weight
2023-03-21 Fortgesetzt Wells Fargo Overweight
2023-01-04 Bestätigt H.C. Wainwright Neutral
2022-12-20 Hochstufung Jefferies Hold → Buy
2022-11-01 Herabstufung H.C. Wainwright Buy → Neutral
2022-10-21 Herabstufung SVB Leerink Outperform → Mkt Perform
2022-10-04 Fortgesetzt Wells Fargo Overweight
2022-05-05 Hochstufung Guggenheim Neutral → Buy
2022-03-15 Eingeleitet Evercore ISI Outperform
2021-12-10 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-11-17 Fortgesetzt Guggenheim Neutral
2021-10-07 Eingeleitet Jefferies Hold
2021-03-31 Eingeleitet Credit Suisse Outperform
2021-02-25 Herabstufung SVB Leerink Outperform → Mkt Perform
2021-02-08 Fortgesetzt H.C. Wainwright Buy
2021-01-25 Herabstufung Citigroup Buy → Neutral
2020-09-29 Fortgesetzt JP Morgan Neutral
2020-08-06 Eingeleitet SVB Leerink Outperform
2020-01-10 Eingeleitet Wolfe Research Outperform
2019-12-09 Eingeleitet JP Morgan Neutral
2019-11-25 Eingeleitet H.C. Wainwright Buy
2019-11-20 Eingeleitet Guggenheim Buy
2019-09-30 Hochstufung Raymond James Outperform → Strong Buy
2019-08-30 Eingeleitet Stifel Buy
2019-07-18 Eingeleitet Deutsche Bank Buy
2018-05-11 Hochstufung Barclays Underweight → Equal Weight
2018-03-19 Eingeleitet Raymond James Outperform
Alle ansehen

Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten

pulisher
Jun 18, 2025

Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500 - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World

Jun 17, 2025
pulisher
Jun 12, 2025

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) (ZYME) - Seeking Alpha

Jun 12, 2025
pulisher
Jun 12, 2025

Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Transcript : Zymeworks Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN

Jun 10, 2025
pulisher
Jun 09, 2025

ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - Revista ADVFN

Jun 09, 2025
pulisher
Jun 03, 2025

Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Nuveen Asset Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

BNP Paribas Financial Markets Takes $108,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN

May 31, 2025
pulisher
May 31, 2025

Ameriprise Financial Inc. Sells 15,800 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World

May 31, 2025
pulisher
May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire

May 30, 2025
pulisher
May 30, 2025

Zymeworks gets China's conditional nod for BeOne-partnered cancer treatment - Seeking Alpha

May 30, 2025
pulisher
May 30, 2025

Zymeworks Inc. Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-High expression (IHC3+ Biliary Tract Cancer - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer - TipRanks

May 30, 2025
pulisher
May 30, 2025

Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire

May 30, 2025
pulisher
May 29, 2025

Zymeworks Inc. announces the closing of its previously announced underwritten public offering - McCarthy Tétrault

May 29, 2025
pulisher
May 28, 2025

Zymeworks Inc. (NYSE:ZYME) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 28, 2025
pulisher
May 23, 2025

What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings? - Defense World

May 23, 2025
pulisher
May 22, 2025

Zymeworks Showcases Oncology Advances at Major Conferences - TipRanks

May 22, 2025
pulisher
May 22, 2025

Zymeworks Inc. Showcases Azymetric™ Platform and Clinical Progress of Ziihera® at ASCO and ESMO Conferences - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire

May 22, 2025
pulisher
May 22, 2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire Inc.

May 22, 2025
pulisher
May 22, 2025

TD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World

May 22, 2025
pulisher
May 22, 2025

TD Securities Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World

May 22, 2025
pulisher
May 21, 2025

Zymeworks Announces Participation in Upcoming Investor Conferenc - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Zymeworks to Engage Investors at Upcoming Conferences - TipRanks

May 21, 2025
pulisher
May 21, 2025

Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times

May 21, 2025
pulisher
May 21, 2025

Zymeworks Inc. Announces Upcoming Participation in Key Investor Conferences in June 2025 - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Zymeworks Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Citi Healthcare Events - Stock Titan

May 21, 2025
pulisher
May 21, 2025

Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust Corp - Defense World

May 21, 2025
pulisher
May 20, 2025

TD Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Zymeworks (ZYME) Initiated as a Buy by TD Cowen Due to Strong Pi - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Zymeworks (ZYME) Receives New Buy Rating from TD Securities | ZYME Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

TD Cowen Initiates Coverage on Zymeworks With Buy Rating - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Zymeworks (ZYME) Gains Favor with Buy Rating from TD Cowen | ZYM - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the American Th - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Zymeworks (ZYME) Reveals Promising Preclinical Results for ZW152 - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Zymeworks Shows Positive Preclinical Data for Experimental Respiratory Imflammation Treatment - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Zymeworks Unveils Promising Preclinical Data for Novel Respiratory Treatment - TipRanks

May 19, 2025
pulisher
May 19, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference | ZYME Stock News - GuruFocus

May 19, 2025
pulisher
May 18, 2025

The Manufacturers Life Insurance Company Sells 1,089 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World

May 18, 2025
pulisher
May 16, 2025

Price T Rowe Associates Inc. MD Raises Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World

May 16, 2025
pulisher
May 15, 2025

Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet - NewsBreak: Local News & Alerts

May 15, 2025

Finanzdaten der Zymeworks Inc.-Aktie (ZYME)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Zymeworks Inc.-Aktie (ZYME) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
EcoR1 Capital, LLC
Director
May 19 '25
Buy
11.78
5,919
69,738
17,883,908
EcoR1 Capital, LLC
Director
Apr 16 '25
Buy
11.16
73,953
825,589
17,773,727
EcoR1 Capital, LLC
Director
Apr 17 '25
Buy
11.52
54,760
630,819
17,828,487
EcoR1 Capital, LLC
Director
Apr 04 '25
Buy
11.17
196,438
2,193,800
17,699,774
EcoR1 Capital, LLC
Director
Apr 03 '25
Buy
11.84
120,770
1,430,170
17,503,336
EcoR1 Capital, LLC
Director
Apr 02 '25
Buy
11.85
74,360
881,017
17,382,566
EcoR1 Capital, LLC
Director
Apr 01 '25
Buy
11.60
48,658
564,647
17,308,206
EcoR1 Capital, LLC
Director
Mar 31 '25
Buy
11.75
4,397
51,658
17,259,548
EcoR1 Capital, LLC
Director
Mar 25 '25
Buy
12.91
53,501
690,452
17,211,303
EcoR1 Capital, LLC
Director
Mar 26 '25
Buy
12.24
43,848
536,857
17,255,151
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):